Integra LifeSciences Opens New Center of Innovation and Learning
11 Maio 2023 - 5:30PM
Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading
global medical technology company, hosted a ribbon-cutting ceremony
on Thursday, May 11, 2023, to commemorate the grand opening and
dedication of its new center of innovation and learning to Dr.
Richard E. Caruso, late founder of the company, in Plainsboro, New
Jersey.
“This new state-of-the-art 14,000 square foot research and
development (R&D) facility is dedicated to pioneering new
advances in treatment pathways and setting new standards of care to
restore patient’s lives,” said Jan De Witte, Integra’s president
and chief executive officer. “We are proud to honor Dr. Caruso’s
legacy and contributions to regenerative medicine by naming our new
facility, the Dr. Richard E. Caruso Center of Innovation and
Learning.”
As Robert T. Davis, Jr., executive vice president and president
of Integra’s Tissue Technologies global product division shared
during the ceremony, “This new facility reinforces our commitment
to deliver cutting-edge regenerative technologies to address unmet
clinical needs. In addition, it will be an important site for
learning as we plan to host many educational programs for our
customers and colleagues worldwide, which is an important part of
our mission.”
Dr. Caruso, former chairman of the board and CEO of Integra
LifeSciences, founded Integra LifeSciences in 1989 with a vision
that the human body could be enabled to regenerate many of its own
damaged or diseased tissues. Through his vision, Integra became the
first company to develop and bring to market a tissue regeneration
product, Integra® Dermal Regeneration Template, which was approved
by the FDA in 1996 as a skin replacement system with a claim for
regeneration of dermal tissue in the treatment of life-threatening
burns and repair of scar contractures.
Distinguished guests included staff members from the offices of
New Jersey Representative Bonnie Watson Coleman and Senator Cory
Booker, as well as Plainsboro Mayor Peter Cantu. Guests were given
a tour of the new R&D facility following the dedication
ceremony.
Integra is a $1.5 billion global company with 3,700 employees
worldwide, 800 of which are based at one of its New Jersey
facilities, and was also recently listed as a “Best Place to Work
in New Jersey” by NJBIZ and Best Companies Group.
About Integra LifeSciencesIntegra LifeSciences
is a global leader in regenerative tissue technologies and
neurosurgical solutions dedicated to limiting uncertainty for
clinicians so they can focus on providing the best patient care.
Integra offers a comprehensive portfolio of high quality,
leadership brands that include AmnioExcel®, Aurora®, Bactiseal®,
BioD™, CerebroFlo®, CereLink® Certas® Plus, Codman®, CUSA®, Cytal®,
DuraGen®, DuraSeal®, DuraSorb®, Gentrix®, ICP Express®, Integra®,
Licox®, MAYFIELD®, MediHoney®, MicroFrance®, MicroMatrix®,
NeuraGen®, NeuraWrap™, PriMatrix®, SurgiMend®, TCC-EZ® and
VersaTru®. For the latest news and information about Integra and
its products, please visit www.integralife.com.
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties and reflect the Company's
judgment as of the date of this release. All statements, other than
statements of historical fact, are statements that could be deemed
forward-looking statements. Such forward-looking statements involve
risks and uncertainties that could cause actual results to differ
from predicted results. These risks and uncertainties include
market conditions and other factors beyond the Company's control
and the economic, competitive, governmental, technological, and
other factors identified under the heading "Risk Factors" included
in item 1A of Integra's Annual Report on Form 10-K for the year
ended December 31, 2021, and information contained in subsequent
filings with the Securities and Exchange Commission. These
forward-looking statements are made only as the date thereof, and
the Company undertakes no obligation to update or revise the
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACT: Integra LifeSciences Holdings
Corporation
Investor Relations:Chris Ward(609)
772-7736chris.ward@integralife.com
Media Contact:Laurene Isip(609)
208-8121laurene.isip@integralife.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/17e8bd6a-dbb6-4c49-a850-e80d2af26b27
Integra LifeSciences (NASDAQ:IART)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Integra LifeSciences (NASDAQ:IART)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024